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Valorization is officially defined as “the process of value creation out of knowledge by making 
this knowledge suitable and available for economic and societal utilization and to translate this 
into high-potential products, services, processes and industrial activity”. 
  In this chapter, the implications of our findings on the relevant socioeconomic 
domains of ‘health care and society’ and ‘patients and professionals’ are discussed. 
Chronic diseases strain the healthcare system because these can only be managed, not cured. 
Patients are often diagnosed at young age, resulting in a longstanding use of healthcare 
resources and high costs. Inflammatory bowel disease [IBD] is most often diagnosed in young 
adulthood [20-40 years of age] and most patients require follow-up in the outpatients’ clinic. 
During disease course, many require expensive medical treatment and at some point in-
hospital medical or surgery therapy1-6, resulting in additional healthcare costs.7 Based on 
clinical data from IBD patients diagnosed between 1970 and 1993, Silverstein et al. estimated 
the life-time direct costs of Crohn’s disease [CD] to be $ 39,906. Major cost driver at that 
time was intestinal surgery, accounting for 44% of the total costs.7 More recently, Van der 
Valk et al. estimated the annual costs of CD in the Netherlands at € 7,835 per year.8 Apart 
from these direct costs, indirect costs are also noteworthy in IBD. The chronicity of the disease 
and its unpredictable, fluctuating course can have major impact on work, leisure time and 
participation in society. For instance, absenteeism and reduced work productivity are often 
present in IBD patients. Valid estimates of the total indirect costs of IBD are difficult to obtain, 
but European studies presented estimates between $ 5,128 – $ 14,136 per year.9 Several 
findings discussed in the present thesis indicated that the costs of IBD are higher than 
previously expected and will further increase in the near future.   
  First, in Chapter 3, we showed that the incidence of IBD is also increasing in the 
Netherlands, with annual increases of 6% [CD] and 4% [UC] between 1991 and 2010. Data 
from the most-recent years of the study period even showed higher rates. The IBD incidence 
in South Limburg is among the highest reported in literature10, illustrating a high disease 
burden in the Netherlands. Based on the South Limburg data, an estimation of the nationwide 
IBD prevalence was made, illustrating that 80,627 patients suffer from IBD [2010], which is 
much higher than previously assumed [55,000]. The ongoing rise in IBD incidence warrants 
further research on its etiology, in order to come to preventive measures. As discussed in 
Chapter 10, environmental factors are interesting targets, since they are modifiable and 
previous research have found associations between the onset of IBD and diet, smoking, 
urbanization and air pollution.11 However, the interaction between host and environment is 
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complex and relations are preferably studied using system biology modeling, incorporating 
factors as from early life [exposome approach].  
  Second, in Chapters 5 and 6, we showed that the medical management of IBD has 
changed towards an earlier and more frequent use of immunomodulators and anti-TNFα 
agents. In particular, anti-TNFα therapy is expensive [estimated at € 10,000 - € 15,000 per 
patient per year].  A Dutch multicenter study illustrated that current IBD healthcare costs are 
mainly driven by medical therapy [71% for CD, 59% for UC], rather than by hospitalizations 
and surgery [20% for CD, 25% for UC].12 Because recent guidelines advocate an earlier and 
more frequent use of biologicals13 and new treatment strategies also propose a more frequent 
use of biologicals [Chapter 10 ], rising medication costs can be expected. Part of the expected 
rise will be tempered by the availability of so-called ‘biosimilars’, generic formulations of 
biological agents. Nevertheless, rising medication costs will inevitably lead to rising total 
healthcare costs, unless medical therapy results in an improved disease outcome. In that case, 
costs of frequent hospital visits, hospital admissions and surgery may attenuate. In this thesis, 
however, we found no significant association between the improved disease outcome and the 
use of immunomodulator anti-TNFα therapy. In literature, anti-TNFα therapy was already 
found to be cost-effective though, both as monotherapy14,15 and combination therapy16, 
although efficacy data mainly derive from registration trials, rather than from real-world 
practice. Moreover, data on cost-effectiveness on the long-term is lacking. Future studies 
should therefore focus on the long-term cost-effectiveness of biological therapy and future 
trials on new treatment strategies should include cost-utility analyses. 
  Third, current and future treatment strategies are aimed at ‘tight control’, which 
encompasses regular blood and stool tests, scheduled visits at the outpatient clinic and a low-
threshold use of endoscopic or radiologic modalities to assess mucosal inflammation. Such 
strategies can be expensive, unless they prove their selves to be cost effective in terms of 
better disease control and, consequent, avoidance of healthcare costs [outpatient visits, 
hospital admission, surgery].   
  Altogether, the findings reported in this thesis indicate that IBD is putting more 
pressure on our healthcare system than previously thought and a further increase in direct 
health care costs can be expected. It is of interest whether the interventions studied in this 
thesis result in less absenteeism and can thereby lower the indirect costs. These conclusions 
demand for action in order to maintain affordable, high-quality IBD care. Next to the 
aforementioned suggestions for further research, it is important to think of restructuring IBD 
care to maintain safe, high-quality care, while reducing healthcare costs. Over the past years, 
there has been an increasing interest in the use of eHealth tools in chronic diseases, such as 
congestive heart failure17 and COPD18. For IBD, the telemedicine tool ‘mijnIBDcoach’ is 
available, which follows IBD patients via monthly monitoring modules on tablet or smartphone. 
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Its use was studied in a large randomized controlled trial, which showed that patients using 
mijnIBDcoach required less outpatient visits and hospital admissions, while patient satisfaction, 
risk of flares and the number of courses of corticosteroids were not different from the control 
group.19 Thus, telemedicine is a promising and safe management tool with the potential of 
being cost-effective.  
Both patients and professionals benefit from having up-to-date information on the IBD 
incidence and its course.   
  First, the increasing high pressure of IBD on healthcare and its observed high 
prevalence in the Netherlands warrants the need for more funding for scientific research. 
Second, by illustrating that IBD is an increasingly common disease, the present thesis also 
supports initiatives for improving knowledge about IBD in the general population. Better 
knowledge may limit patient delay in the diagnostic process and may help reducing the stigma 
of a disease characterized by frequent bowel movements and urgency. Third, information on 
the actual disease course helps physicians to educate patients better on their chronic disease, 
thereby improving patient empowerment. Patient empowerment and engagement in disease 
monitoring may subsequently lead to better treatment response, patient satisfaction and a 
more efficient utilization of healthcare resources.20 Information on the [long-term] disease 
outcome also contributes to shared decision making, for example in a discussion on the need 
for another medical therapy or surgery. Next to education, insight in the real-world 
effectiveness of current treatment strategies contributes to the development of better disease 
management. Real-world treatment effectiveness data can help in the process of clinical 
decision making in situations in which data from randomized controlled trials are lacking, 
which is the case in the management of specific populations [e.g. elderly] and in therapy 
selection [e.g. the choice of one anti-TNFα agent over another]. Reflecting on the latter, we 
observed a similar real-world effectiveness of infliximab and adalimumab in CD [Chapter 9 ], 
which emphasizes that the choice between these two agents can be made based on individual 
preferences of the physician or patient. In the near future, comparative effectiveness analyses 
in large real-world cohorts may also help in the upcoming challenge which biological therapy 
is best for a specific patient [personalized treatment]. Hereby, the time spent on suboptimal 
therapy may be minimized, which will hopefully lead to a better disease outcome and quality 
of life on both the short and long term. 
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